Low-dose naltrexone (LDN) does appear to help with certain types of chronic pain, particularly conditions driven by inflammation or nervous system sensitization like fibromyalgia, complex regional pain syndrome, and inflammatory bowel disease. The evidence is still growing, but clinical trials and real-world use consistently show meaningful pain reduction in many patients. The catch: naltrexone is not FDA-approved for pain. It’s used off-label at doses far below its approved form, typically between 0.1 and 4.5 mg per day compared to the standard 50 mg dose used for alcohol dependence.
How Low-Dose Naltrexone Reduces Pain
Naltrexone at full strength is an opioid blocker. It locks onto opioid receptors and prevents anything from activating them. At very low doses, though, it does something counterintuitive: it creates a brief, partial blockade that triggers your body to compensate by producing more of its own natural painkillers, including endorphins and enkephalins, while also increasing the number of opioid receptors available to receive them. This “rebound” effect, first described by Dr. Ian Zagon and colleagues, has been demonstrated repeatedly in research. The result is a net boost in your body’s own pain-relief system.
LDN also appears to calm overactive immune cells in the brain and spinal cord. In chronic pain conditions, these immune cells can become stuck in an inflammatory state, amplifying pain signals that should otherwise quiet down. At doses generally between 1.0 and 4.5 mg per day, naltrexone suppresses a specific receptor on these cells that drives neuroinflammation. This dual action, both enhancing your natural opioids and reducing nervous system inflammation, is what makes LDN different from conventional painkillers.
Evidence for Fibromyalgia
Fibromyalgia has the strongest body of clinical trial evidence for LDN. A systematic review and meta-analysis published in the Annals of Medicine and Surgery found that LDN was significantly better than placebo at reducing pain intensity in fibromyalgia patients. When the researchers removed one study that used a different pain scale, the effect became even clearer and the results across studies became highly consistent. The review concluded that LDN is considered effective for fibromyalgia treatment.
One nuance: LDN reduced how much pain patients reported feeling, but it did not significantly raise their mechanical pain threshold, meaning the point at which pressure becomes painful. This suggests LDN works more on the brain’s processing of pain signals and the inflammatory environment around nerves than on the sensitivity of pain receptors themselves.
Evidence for Other Pain Conditions
Complex regional pain syndrome (CRPS), one of the most severe chronic pain conditions, has also shown responsiveness to LDN. A 2017 clinical trial published in Pain Medicine found that LDN provided significant pain relief and improved physical function in CRPS patients without the side effects associated with opioids. Case reports describe patients regaining limb mobility after starting treatment.
Inflammatory bowel disease is another area where LDN shows promise, and the pain relief here comes partly from reducing the underlying gut inflammation. In a pilot study at Erasmus MC, 74.5% of patients who weren’t responding to conventional therapy experienced clinical improvement after 12 weeks on LDN, with 25.5% reaching full remission. A subsequent randomized controlled trial found an 88% response rate in the LDN group compared to 40% on placebo. A separate open-label study in 17 patients showed clinical remission in 67% after 12 weeks. Pediatric patients with IBD also showed significant improvement, with 67% experiencing clinical improvement and 25% achieving remission in 8 weeks.
Dosing Is More Individual Than You Might Expect
Most articles about LDN cite 4.5 mg per day as the standard dose. In practice, effective doses vary widely. An observational study published in the Journal of Pain Research found that established doses ranged from 0.1 to 5.6 mg per day, with the most common effective doses clustering at 2 mg or less. The effective dose for any given patient appears to be highly individual.
Typical protocols start at 0.1 mg per day and increase by 0.1 mg every three days. Patients continue this slow titration until they find relief or reach a ceiling of around 6.0 mg, at which point LDN is considered ineffective for them. This gradual approach helps identify the lowest effective dose and minimizes side effects. Different dose ranges also appear to work through different mechanisms: extremely tiny doses (below 0.001 mg) enhance opioid signaling directly, while the 1.0 to 4.5 mg range primarily targets neuroinflammation.
Side Effects Are Generally Mild
LDN is well tolerated compared to most pain medications. No serious adverse effects have been reported in clinical studies. That said, about half of patients in one retrospective study experienced some side effect, most commonly nausea (the most frequent, with the majority of cases being transient), fatigue, vivid dreams, and insomnia. The vivid dreams finding is consistent across multiple trials. A meta-analysis of fibromyalgia studies found that patients on LDN were about 2.4 times more likely to report vivid dreams than those on placebo.
Most of these effects fade as the body adjusts. The slow titration schedule helps, since starting at a very low dose gives your system time to adapt before the dose increases.
Critical Safety Concern With Opioids
If you currently take any opioid medication, including tramadol, methadone, or buprenorphine, you cannot simply start naltrexone. Because naltrexone blocks opioid receptors, taking it while opioids are still active in your system can trigger severe precipitated withdrawal, which in some cases requires hospitalization. The FDA label for naltrexone explicitly contraindicates its use in anyone receiving opioid analgesics or currently dependent on opioids.
Patients previously dependent on short-acting opioids need a minimum 7 to 10 day opioid-free period before starting naltrexone. For those transitioning from longer-acting opioids like methadone or buprenorphine, the vulnerable period extends to at least two weeks. This is one of the most important practical barriers for chronic pain patients, since many are already on opioid therapy when they learn about LDN.
Getting a Prescription
Because naltrexone is only commercially available in 50 mg tablets (approved for alcohol and opioid use disorders), low-dose formulations must be prepared by a compounding pharmacy. Your doctor writes a prescription for the specific low dose, and a compounding pharmacy creates it as a custom capsule or liquid. The American Academy of Family Physicians has noted that this compounding requirement limits access for some patients, as not all areas have compounding pharmacies and insurance coverage varies. Costs typically run between $30 and $60 per month out of pocket, though this varies by pharmacy and location.
LDN remains entirely off-label for pain. Not all physicians are familiar with the evidence, so finding a provider experienced with LDN prescribing sometimes requires searching specifically for integrative or pain medicine practitioners who include it in their practice.